MELBOURNE, Australia, June 1, 2026– 4DMedical Limited (ASX: 4DX), a global leader in advanced respiratory imaging, today announced a major expansion into Europe through signing a binding agreement to acquire contextflow GmbH, an Austria-based category leader in AI-driven lung cancer detection and radiology workflow solutions.
The transaction provides 4DMedical with an immediate, on-the-ground European comprehensive commercial platform, significantly accelerating its global growth strategy and establishing operations across North America, Europe and Australia.
Integrating AI and Functional Lung Imaging
While the transaction is strategically focused on geographic expansion, it also enhances 4DMedical’s technology platform. contextflow’s AI-based detection and workflow tools, particularly in lung cancer screening, complement 4DMedical’s functional imaging capabilities, which enable quantitative assessment of ventilation, perfusion and lung mechanics.
Together, the combined portfolio supports a more complete clinical pathway:
• Detection and triage of lung abnormalities
• Diagnostic assessment using functional imaging
• Monitoring and disease progression tracking
This integrated offering positions 4DMedical as a differentiated provider of both structural and functional lung insights for radiology and respiratory care.
Strategic European Market Entry
Europe represents a critical growth market for advanced imaging, lung cancer screening and AIenabled clinical decision support. Through the acquisition of contextflow, 4DMedical gains:
• A European-based team with established commercial and technical expertise
• An existing customer base and clinical footprint across Europe
• A CE-marked product suite already deployed in routine clinical workflows
• A regulatory platform aligned with Europe’s Medical Device Regulation (MDR)
This foundation enables 4DMedical to bypass the time and complexity of establishing a new regional presence, creating an immediate pathway to revenue and scale.
Accelerating Commercialisation and Cross-Selling
The European footprint creates near-term opportunities to expand adoption of 4DMedical’s broader portfolio, including its functional lung imaging technologies. By combining complementary product suites, the company is positioned to:
• Introduce functional lung imaging solutions into established European radiology workflows
• Cross-sell into an existing installed base of customers
• Expand into markets with established reimbursement pathways, including Germany
• Accelerate time to market for new AI-enabled solutions
The addition of a commercially active, MDR-compliant platform further reduces regulatory friction and enables scalable growth across multiple European markets.
Strengthening a Transatlantic Clinical Network
The expansion significantly enhances 4DMedical’s engagement with key opinion leaders (KOLs) across Europe, strengthening its global clinical network. Combined with existing relationships in the United States, this creates a transatlantic ecosystem that supports gaster clinical validation and real-world evidence generation